Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Omeros Corporation stock | $14.3

Own Omeros Corporation stock in just a few minutes.

Fact checked

Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 258 staff and has a trailing 12-month revenue of around USD$96.6 million.

How to buy shares in Omeros Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Omeros Corporation. Find the stock by name or ticker symbol: OMER. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Omeros Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$14.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Omeros Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Omeros Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Omeros Corporation share price

Use our graph to track the performance of OMER stocks over time.

Omeros Corporation shares at a glance

Information last updated 2020-11-30.
Latest market closeUSD$14.3
52-week rangeUSD$8.5 - USD$20.6
50-day moving average USD$11.105
200-day moving average USD$12.8341
Wall St. target priceUSD$32.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.08

Buy Omeros Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Omeros Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Omeros Corporation price performance over time

Historical closes compared with the close of $14.3 from 2020-12-09

1 week (2021-01-08) -10.68%
1 month (2020-12-16) -5.80%
3 months (2020-10-15) 24.78%
6 months (2020-07-15) 0.14%
1 year (2020-01-15) -0.07%
2 years (2019-01-15) 2.14%
3 years (2018-01-12) 19.6
5 years (2016-01-15) 43.86%

Omeros Corporation financials

Revenue TTM USD$96.6 million
Gross profit TTM USD$40 million
Return on assets TTM -39.46%
Return on equity TTM 0%
Profit margin -134.59%
Book value $-2.648
Market capitalisation USD$701.9 million

TTM: trailing 12 months

Shorting Omeros Corporation shares

There are currently 12.2 million Omeros Corporation shares held short by investors – that's known as Omeros Corporation's "short interest". This figure is 2% down from 12.4 million last month.

There are a few different ways that this level of interest in shorting Omeros Corporation shares can be evaluated.

Omeros Corporation's "short interest ratio" (SIR)

Omeros Corporation's "short interest ratio" (SIR) is the quantity of Omeros Corporation shares currently shorted divided by the average quantity of Omeros Corporation shares traded daily (recently around 643022.79217345). Omeros Corporation's SIR currently stands at 18.91. In other words for every 100,000 Omeros Corporation shares traded daily on the market, roughly 18910 shares are currently held short.

However Omeros Corporation's short interest can also be evaluated against the total number of Omeros Corporation shares, or, against the total number of tradable Omeros Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omeros Corporation's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Omeros Corporation shares in existence, roughly 200 shares are currently held short) or 0.2063% of the tradable shares (for every 100,000 tradable Omeros Corporation shares, roughly 206 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Omeros Corporation.

Find out more about how you can short Omeros Corporation stock.

Omeros Corporation share dividends

We're not expecting Omeros Corporation to pay a dividend over the next 12 months.

Have Omeros Corporation's shares ever split?

Omeros Corporation's shares were split on 2 October 2009.

Omeros Corporation share price volatility

Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $8.5 up to $20.6. A popular way to gauge a stock's volatility is its "beta".

OMER.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.6223. This would suggest that Omeros Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Omeros Corporation overview

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site